Combining Esketamine and Prolonged Exposure Treatment for PTSD (Post Traumatic Stress Disorder)
Key facts
- Who runs it
- The University of Texas Health Science Center at San Antonio
- Where
- San Antonio, United StatesSee the site
- Trial code
- Status
- Completed
- Phase
- Phase 1/2
- People taking part
- 4 people enrolled
- Started
- 9 Jun 2025
- Ended
- 16 Jan 2026
- Type of study
- Interventional
- Treatments tested
- Esketamine (Intranasal Spray)
- Massed Prolonged Exposure (PE)
- Record updated
- 28 January 2026
Who can take part
- Age
- 18 years to 65 years
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 24 criteriaShow less
Who can take part
- Individual between the ages of 18-65 years old (Young adults [18 to 24 years old] must not be taking an antidepressant)
- PTSD diagnosis as assessed by Clinician-Administered Posttraumatic Stress Scale (CAPS-5)
- Able to speak and read English (due to standardization of outcome measures)
- On stable doses of current medications for at least 4 weeks
- Weigh between 50-100 kg (110-220 pounds)
Who cannot take part
- Young adults (18-24) currently taking any antidepressant
- Moderate or greater severity for alcohol or substance use disorder (DSM-5) in the previous six months
- Current use (with past 4 weeks) of any prohibited concomitant medications
- Benzodiazepines, other medications, sedatives, acute alcohol use, or recreational drug use that would put patients at risk in the judgment of clinical providers)
- Lifetime history of psychotic disorder or history of significant psychotic symptoms
- Lifetime history of manic episode
- A history of ketamine or phencyclidine abuse
- Other psychiatric disorders severe enough to warrant designation as the primary disorder as determined by clinician judgment
- Uncontrolled hypertension or tachycardia
- A history of sensitivity or adverse reaction to ketamine or its excipients
- An unstable medical, cardiovascular, pulmonary, or neurological condition that the investigator considers a contraindication to ketamine administration
- Aneurysmal vascular disease (including thoracic and abdominal aorta, intracranial and peripheral arterial vessels) or arteriovenous malformation
- Intracerebral hemorrhage
- History of nasal surgery or nasal obstructions experienced as an adult
- Evidence of a traumatic brain injury severe enough to interfere with comprehension and responding to the baseline screening questionnaires
- Current suicidal ideation severe enough to warrant immediate attention (as determined by the Depressive Symptoms Index-Suicidality Subscale and corroborated by a clinical risk assessment by a credentialed provider)
- Planned use of ketamine (i.e., for pain control) or participation in another trauma-focused psychotherapy during the time of the study
- Pregnancy or breastfeeding; women of childbearing potential unwilling to utilize reliable methods of contraception
- Inability to arrange for assisted transportation on ketamine treatment days due to recommendation that patient not drive for the remainder of the day following a ketamine treatment
Where in United States
- The University of Texas Health Science Center at San AntonioSan Antonio, United States
About the trial
What the trial wants to find out
This study is being done to see if Prolonged Exposure (PE), a well-researched, very effective individual (one-to-one) behavioral therapy designed to help people to directly deal with traumatic events they have suffered in the past, can be combined with intranasal esketamine (ketamine) for the treatment of posttraumatic stress disorder (PTSD) to enhance treatment benefits. Ketamine nasal spray is a drug approved by the U.S. Food \& Drug Administration (FDA) for treatment resistant depression. Combined with PE, intranasal ketamine may help to augment PE and further reduce participants' PTSD symptoms.
The group in the trial
- Esketamine combined with Prolonged Exposure for PTSDTreatment being tested
Esketamine (intranasal ketamine) will be administered 6 times over a 2-week period after administering PE sessions
Treatment: Esketamine (Intranasal Spray) and Massed Prolonged Exposure (PE)
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- Combining Esketamine and Prolonged Exposure for PTSD: A Proof-of-Concept Clinical Trial
- Record updated
- 28 January 2026